amiloride has been researched along with Multiple Sclerosis, Chronic Progressive in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandran, S; Chataway, J; Connick, P; de Angelis, F; Foley, P; Parker, RA; Weir, CJ; Young, C | 1 |
| Barkhof, F; Bastow, R; Braisher, M; Chandran, S; Chataway, J; Connick, P; Cranswick, G; De Angelis, F; Doshi, A; Gandini Wheeler-Kingshott, CA; Giovannoni, G; Hawkins, C; John, N; MacManus, D; Ourselin, S; Parker, RA; Pavitt, SH; Plantone, D; Prados Carrasco, F; Ross, M; Sharrack, B; Stallard, N; Stutters, J; Weir, CJ | 2 |
| Barkhof, F; Chataway, J; DeAngelis, F; Doshi, A; Gandini Wheeler-Kingshott, CAM; John, NA; MacManus, D; Marshall, I; Monteverdi, A; Parker, RA; Plantone, D; Prados, F; Schneider, T; Solanky, BS; Stutters, J; Weir, CJ | 1 |
| Arun, T; Cavey, A; Craner, M; de Ruiter, MB; Fugger, L; Gelineau-Morel, R; Jenkinson, M; Leite, MI; Matthews, L; Palace, J; Rovira, A; Sbardella, E; Tomassini, V; Vergo, S | 1 |
4 trial(s) available for amiloride and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Topics: Adult; Amiloride; Double-Blind Method; Fluoxetine; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuralgia; Riluzole | 2022 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Topics: Administration, Oral; Adult; Amiloride; Brain; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2020 |
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Topics: Adult; Amiloride; Aspartic Acid; Biomarkers; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fluoxetine; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroimaging; Neuroprotective Agents; Proton Magnetic Resonance Spectroscopy; Protons; Riluzole | 2020 |
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple scl
Topics: Adult; Amiloride; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Riluzole; Treatment Outcome | 2018 |
1 other study(ies) available for amiloride and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Topics: Acid Sensing Ion Channel Blockers; Acid Sensing Ion Channels; Adult; Aged; Aged, 80 and over; Amiloride; Brain; Diffusion Tensor Imaging; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Nerve Fibers, Myelinated; Neuroprotective Agents; Pilot Projects; Treatment Outcome | 2013 |